A clinical trial listing tied to bivalirudin was updated on September 24, 2026. The study, titled "PACE: Prostacyclin AntiCoagulation in ECMO," is registered as Phase 1/Phase 2. Its current status is listed as not yet recruiting.
The trial record, identified as NCT07837869, is publicly available on ClinicalTrials.gov. No participants have been enrolled yet based on the current status.
Bivalirudin remains an approved compound. This update reflects only the registration status of the trial as of the listed date, and no outcomes, safety findings, or efficacy data are included in this record. As the study has not begun recruiting, no results or interim data are currently available for review.
Readers interested in learning more about how bivalirudin is used and studied can consult the compound overview for additional context and background information on its approved status and general profile.